Cargando…

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

BACKGROUND: Antitumor vaccines targeting tumor-associated antigens (TAAs) can generate antitumor immune response. A novel vaccine platform using adenovirus 5 (Ad5) vectors [E1–, E2b–] targeting three TAAs—prostate-specific antigen (PSA), brachyury, and MUC-1—has been developed. Both brachyury and th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bilusic, Marijo, McMahon, Sheri, Madan, Ravi A, Karzai, Fatima, Tsai, Yo-Ting, Donahue, Renee N, Palena, Claudia, Jochems, Caroline, Marté, Jennifer L, Floudas, Charalampos, Strauss, Julius, Redman, Jason, Abdul Sater, Houssein, Rabizadeh, Shahrooz, Soon-Shiong, Patrick, Schlom, Jeffrey, Gulley, James L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Clinical/Translational Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7993215/ https://www.ncbi.nlm.nih.gov/pubmed/33762322 http://dx.doi.org/10.1136/jitc-2021-002374

Ejemplares similares

A Phase I Trial Using a Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury)‐Based Immunotherapy Vaccine Regimen in Patients with Advanced Cancer
por: Gatti‐Mays, Margaret E., et al.
Publicado: (2019)

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer
por: DeMaria, Peter J, et al.
Publicado: (2021)

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Very Early PSA Response to Abiraterone in mCRPC Patients: A Novel Prognostic Factor Predicting Overall Survival
por: Facchini, Gaetano, et al.
Publicado: (2016)

Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives
por: Taghizadeh, H., et al.
Publicado: (2019)

Radium-223 Treatment in mCRPC Patient with Polycythemia Vera
por: de Angelis, Cristina, et al.
Publicado: (2021)

Upregulation of PSMA Expression by Enzalutamide in Patients with Advanced mCRPC
por: Rosar, Florian, et al.
Publicado: (2022)

The role of oncogenic MUC1-C in brachyury-induced immunotherapy resistance
por: David, Justin, et al.
Publicado: (2014)

Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
por: Bilusic, Marijo, et al.
Publicado: (2019)

Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria
por: Velez, Erik M., et al.
Publicado: (2020)

Clinical aspects of mCRPC management in patients treated with radium-223
por: Rizzini, Elisa Lodi, et al.
Publicado: (2020)

Randomized, Double‐Blind, Placebo‐Controlled Phase II Study of Yeast‐Brachyury Vaccine (GI‐6301) in Combination with Standard‐of‐Care Radiotherapy in Locally Advanced, Unresectable Chordoma
por: DeMaria, Peter Joseph, et al.
Publicado: (2021)

Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies
por: Strauss, Julius, et al.
Publicado: (2020)

Generation of human T cells directed against an agonist epitope of Brachyury, a transcription factor involved in human tumor cell epithelial to mesenchymal transition (EMT)
por: Boyerinas, Benjamin, et al.
Publicado: (2013)

Baseline Plasma Tumor DNA (ctDNA) Correlates with PSA Kinetics in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide
por: Conteduca, Vincenza, et al.
Publicado: (2022)

Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Gupta, Eva, et al.
Publicado: (2014)

Current and Emerging Therapies for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Henríquez, Iván, et al.
Publicado: (2021)

Brachyury, a driver of tumor invasiveness and resistance to multiple therapies, is a novel immunotherapy target
por: Palena, Claudia, et al.
Publicado: (2013)

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617
por: Kratochwil, Clemens, et al.
Publicado: (2017)

PROpel trial: Are PARP inhibitors ready to become the first-line treatment for mCRPC?
por: Gaur, Abhay Singh
Publicado: (2022)

Aberrant expression of the embryonic transcription factor brachyury in human tumors detected with a novel rabbit monoclonal antibody
por: Hamilton, Duane H., et al.
Publicado: (2014)

Upregulation of oncogenic MUC1 by the EMT transcription factor brachyury mediates immunotherapy-resistance in tumor cells
por: David, Justin M, et al.
Publicado: (2015)

Phase I, dose-escalation, clinical trial of MVA-Brachyury-TRICOM vaccine demonstrating safety and brachyury-specific T cell responses
por: Heery, Christopher R, et al.
Publicado: (2015)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
por: Gamat-Huber, Melissa, et al.
Publicado: (2020)

Combination therapy for mCRPC with immune checkpoint inhibitors, ADT and vaccine: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2022)

Neoadjuvant PROSTVAC prior to radical prostatectomy enhances T-cell infiltration into the tumor immune microenvironment in men with prostate cancer
por: Abdul Sater, Houssein, et al.
Publicado: (2020)

Androgen Decline and Survival During Docetaxel Therapy in metastatic Castration Resistant Prostate Cancer (mCRPC)
por: Ryan, Charles J, et al.
Publicado: (2019)

Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysis
por: Matsubara, Nobuaki, et al.
Publicado: (2022)

Association between the Immunophenotype of Peripheral Blood from mCRPC Patients and the Outcomes of Radium-223 Treatment
por: Cantó, Elisabet, et al.
Publicado: (2023)

Identification of tumor associated immune responses against brachyury, a transcription factor and driver of EMT, in chordoma patients receiving a yeast-brachyury vaccine (gi-6301)
por: Donahue, Renee N, et al.
Publicado: (2014)

Lessons from the SWITCH trial: changing glucocorticoids in the management of metastatic castration-resistant prostate cancer (mCRPC)
por: Teo, Min Yuen, et al.
Publicado: (2018)

Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients
por: León-Mateos, Luis, et al.
Publicado: (2017)

Ketoconazole for the Treatment of Docetaxel-Naïve Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Systematic Review
por: Tresnanda, Raden Indra, et al.
Publicado: (2021)

Impact of age on antigen-specific T lymphocyte response in patients treated with PSA-TRICOM
por: Singh, Harpreet, et al.
Publicado: (2014)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
por: Qiu, Ping, et al.
Publicado: (2019)

Response to (225)Ac-PSMA-I&T after failure of long-term (177)Lu-PSMA RLT in mCRPC
por: Ilhan, Harun, et al.
Publicado: (2020)

Targeting Feedforward Loops Formed by Nuclear Receptor RORγ and Kinase PBK in mCRPC with Hyperactive AR Signaling
por: Zhang, Xiong, et al.
Publicado: (2021)

Genetic testing for homologous recombination repair (HRR) in metastatic castration-resistant prostate cancer (mCRPC): challenges and solutions
por: Scott, Rodney J., et al.
Publicado: (2021)

Tousled-like kinase 1: a novel factor with multifaceted role in mCRPC progression and development of therapy resistance
por: Khalil, Md Imtiaz, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3ckkbvpo6ctl0dtlf03as86263